MapLight Therapeutics (Nasdaq: MPLT) announced that its Phase 2 ZEPHYR trial of ML-007C-MA met its primary endpoint in adults with ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE